INNIO
10.8.2021 14:10:09 CEST | Business Wire | Press release
INNIO today announced that it has joined the United Nations Global Compact , the world’s largest corporate sustainability initiative. In joining this critical voluntary leadership platform, INNIO continues its path to build on an expanded commitment to its environmental, social and governance (ESG) program. As part of the Global Compact initiative — which is focused on the development, implementation and disclosure of responsible business practices – INNIO proudly aligns itself with thousands of other companies and non-business signatories globally committed to taking responsible business action to create a better world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005096/en/
As part of its relentless pursuit to achieve a climate-neutral, greener and more secure energy future, INNIO established its Sustainability Review Board (SRB), tasked with developing INNIO’s ESG goals and strategy for its Jenbacher and Waukesha businesses in close alignment with INNIO’s growth strategy. In an act to cement its commitment to sustainability, INNIO leadership – in conjunction with its SRB – moved swiftly to become a participant of the Global Compact. INNIO recognized the Global Initiative as being a beacon platform bringing together companies and non-business signatories everywhere to align their operations and strategies with ten principles in the areas of human rights, labor, environment and anti-corruption, and to take action in support of UN goals and issues embodied in the Sustainable Development Goals. Launched in 2000, the UN Global Compact is composed of more than 9,500 companies and 3,000 non-business signatories based in over 160 countries, and more than 70 Local Networks.
“We are delighted to have taken this step to add our voice to that of thousands of others in helping to impact positive change across the world through business,” said Carlos Lange, president and CEO of INNIO. “While our expertise lies in the domain of power generation and gas compression, we recognize that our responsibility does not end with the sustainable production and delivery of electricity and gas compression. As a responsible corporate citizen, we are ethically and morally bound to maintain a responsible role as it pertains to human rights, labor, and anti-corruption as well as the environment. As part of the Global Compact, we are now positioned with our corporate neighbors to advance broader societal goals, such as the UN Sustainable Development Goals, through collaboration and innovation. Together, we can push further and faster to effectively address the world’s most pressing challenges.”
INNIO, a global provider of energy services, equipment and digital solutions for power generation and gas compression at or near the point of use, is relentlessly dedicated to being a model corporate citizen. As part of this effort, INNIO recently took a bold step in advancing sustainability in the power industry to build the first industrial scale hydrogen-fueled power plant . In close collaboration with HanseWerk Natur, INNIO initiated field testing of a 1-megawatt (MW) pilot power plant with a Jenbacher gas engine that represents the world’s first large-scale gas engine in the 1 MW range, capable of operating with variable hydrogen-natural gas mixtures or up to 100% hydrogen. INNIO’s efforts are being recognized as evidenced with its recent accolade of receiving a Silver Medal rating from EcoVadis , placing INNIO Jenbacher in the top 17% of its peers working towards sustainability.
In its capacity as a thought leader, INNIO always seeks new energy sources and better energy solutions to support its customers and their communities, while investing in its Jenbacher and Waukesha product lines and digital solutions to support the energy transition. Its gas engines—many of which have passed stringent sustainability tests for efficiency and energy savings—offer industry-leading emission levels and reduced carbon footprints. INNIO’s gas engine fleet helps to provide a more sustainable future by developing new, innovative low-carbon technologies, such as its hydrogen-ready Jenbacher gas engine technology. Its Waukesha gas engines help customers achieve low emissions and responsibly produce natural gas now and in the future. INNIO’s digital products and solutions play an important role in reduction of emissions and remote smart management of assets for our customers.
In 2021, EcoVadis awarded INNIO Jenbacher a silver medal to honor its engagement for a climate-neutral, greener, and more secure energy future. This places INNIO Jenbacher in the top 17% of its peers working towards sustainability.
About INNIO
INNIO is a leading provider of renewable gas, natural gas, and hydrogen-based solutions and services for power generation and gas compression at or near the point of use. With our Jenbacher and Waukesha gas engines, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by decarbonization, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com . Follow INNIO on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
